Xavier Harland has resigned from his post of chief financial officer at Acasti Pharma Inc, effective immediately. Acasti is an up-and-coming biopharmaceutical company that researches, develops and commercializes krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders.
“I would like to thank Xavier for his contributions over the years and wish him all the best in his future endeavours,” says Andre Godin, interim president and chief financial officer of Acasti. Godin assumed the role effective immediately, and is also chief financial officer of Neptune Technologies and Bioressources.
